Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.29 Average Target Price from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been assigned an average recommendation of "Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $22.29.

A number of equities research analysts have commented on ZVRA shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group increased their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim boosted their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th.

Insider Buying and Selling

In related news, Director John B. Bode purchased 10,000 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were bought at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. This trade represents a 33.33 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company's stock, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,773 shares of company stock valued at $674,176. Insiders own 2.40% of the company's stock.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in Zevra Therapeutics during the fourth quarter worth approximately $53,000. GAMMA Investing LLC boosted its position in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Zevra Therapeutics during the fourth quarter worth about $94,000. XTX Topco Ltd purchased a new stake in shares of Zevra Therapeutics in the third quarter worth about $94,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at about $95,000. Institutional investors and hedge funds own 35.03% of the company's stock.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock traded down $0.29 during trading hours on Friday, hitting $6.56. The stock had a trading volume of 380,642 shares, compared to its average volume of 597,419. The stock has a market capitalization of $355.00 million, a price-to-earnings ratio of -3.33 and a beta of 1.94. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The stock's fifty day moving average is $7.69 and its two-hundred day moving average is $8.14.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to analysts' expectations of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. As a group, analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.